1. Home
  2. Treating AML
  3. What new treatments are in development for AML?

Expert Video - What new treatments are in development for AML?

Acute myeloid leukemia (AML) expert Dr. David Steensma describes encouraging developments in treating AML. This includes the FDA approval of eight new treatments in the past few years and the many clinical trials under way for AML. Medications that target specific mutations responsible for AML are also available as targeted therapy. Some of these target the bone marrow environment where AML cells develop. New chemotherapy drugs for AML are also being developed.

  • Share with family and friends:

Click here to take our SURVEY
Your feedback is important to us! We will use your feedback to develop future areas of content about AML which will help other patients, caregivers and families.

Please rate this content:

Other Modules:

Understanding AML

Understanding AML

Understanding AML-MRC and tAML

Understanding AML-MRC and tAML

Understanding Erythropoiesis

Understanding Erythropoiesis

Diagnosing AML, AML-MRC, and tAML

Diagnosing AML, AML-MRC, and tAML

Treatment Failure and Relapse

Treatment Failure and Relapse

Maintenance and Continuous Treatment

Maintenance and Continuous Treatment

Animation - Treating AML
1. Animation - Treating AML
Slide Show - Treating AML
2. Slide Show - Treating AML
Expert Videos
What are the main treatment options for AML? What are the goals of each treatment?
3. What are the main treatment options for AML? What are the goals of each treatment?
What are induction and consolidation chemotherapy for AML?
4. What are induction and consolidation chemotherapy for AML?
What is a stem cell transplant? Who is a candidate for it?
5. What is a stem cell transplant? Who is a candidate for it?
What is meant by “targeted therapy” for AML?
6. What is meant by “targeted therapy” for AML?
What can be done to treat AML if it doesn’t go into remission or comes back?
7. What can be done to treat AML if it doesn’t go into remission or comes back?
What does “complete remission” and “measurable residual disease” mean?
8. What does “complete remission” and “measurable residual disease” mean?
What does “hematologic recovery” mean?
9. What does “hematologic recovery” mean?
What is the outlook for patients with AML?
10. What is the outlook for patients with AML?
What new treatments are in development for AML?
11. What new treatments are in development for AML?
How can I choose a clinical trial for AML?
12. How can I choose a clinical trial for AML?
What is immunotherapy for AML?
13. What is immunotherapy for AML?
If I have AML, what should I watch out for in daily life?
14. If I have AML, what should I watch out for in daily life?
Patient Videos
Gayle's story: What has been the biggest challenge for you with your AML?
15. Gayle's story: What has been the biggest challenge for you with your AML?
Marcia’s story: What has been the biggest challenge for you with your AML?
16. Marcia’s story: What has been the biggest challenge for you with your AML?
Mike’s story: What has been the biggest challenge for you with your AML?
17. Mike’s story: What has been the biggest challenge for you with your AML?
Thomas' story: What has been the biggest challenge for you with your AML?
18. Thomas' story: What has been the biggest challenge for you with your AML?
Gayle’s story: What has been the biggest success for you with your AML?
19. Gayle’s story: What has been the biggest success for you with your AML?
Marcia’s story: What has been the biggest success for you with your AML?
20. Marcia’s story: What has been the biggest success for you with your AML?
Mike's story: What has been the greatest success and greatest treatment challenge with your AML?
21. Mike's story: What has been the greatest success and greatest treatment challenge with your AML?
Thomas' story: What has been the greatest success and greatest treatment challenge with your AML?
22. Thomas' story: What has been the greatest success and greatest treatment challenge with your AML?

This educational activity has been developed by the Myelodysplastic Syndromes Foundation, Inc. and Mechanisms in Medicine Inc.

This activity is supported by educational grants from AbbVie, Acceleron, Bristol-Myers Squibb, Celgene Corporation, Daiichi Sankyo, Jazz Pharmaceuticals and Takeda Oncology.

This website is part of the Animated Patient™ series developed by Mechanisms in Medicine Inc., to provide highly visual formats of learning for patients to improve their understanding, make informed decisions, and partner with their healthcare professionals for optimal outcomes.